Biology of bone metastases (Q27693653)

publication date

April 2012

1 reference

1 reference

19

1 reference

issue

2

1 reference

page(s)

92-101

1 reference

Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group

cites work

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900203

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900203

Mechanisms of bone metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900203

The bone microenvironment in metastasis; what is special about bone?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900203

Dissemination and growth of cancer cells in metastatic sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900203

Induction of syndecan-1 expression in stromal fibroblasts promotes proliferation of human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900203

Implications of bone metastases and the benefits of bone-targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900203

Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900203

Role of endothelin-1 in osteoblastic bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900203

Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900203

Crosstalk between cancer cells and bone microenvironment in bone metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900203

Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900203

Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900203

Molecular mechanisms and treatment of bone metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900203

Monitoring of skeletal progression of prostate cancer by GFP imaging, X-ray, and serum OPG and PTHrP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900203

Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900203

Radioisotopes for the palliation of metastatic bone cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900203

A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900203

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900203

Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900203

Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900203

Bisphosphonates and time to osteonecrosis development

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900203

Bisphosphonate-associated osteonecrosis of the jaw in breast cancer patients: recommendations for prevention and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900203

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900203

Guanosine nucleotides inhibit different syndromes of PTHrP excess caused by human cancers in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900203

TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900203

The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900203

Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900203

A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900203

Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900203

Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900203

Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900203

Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900203

Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900203

Bisphosphonates in the prevention of disease recurrence: current results and ongoing trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900203

Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900203

Emerging strategies in bone health management for the adjuvant patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900203

The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900203

Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900203

Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900203

Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900203

Ibandronate is effective in preventing skeletal events in patients with bone metastases from colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900203

Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900203

Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900203

Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900203

Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900203

A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900203

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900203

Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900203

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900203

10.1177/107327481201900203

21 January 2018

Identifiers

DOI

0 references

OpenCitations bibliographic resource ID

346226

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

346226

PubMed publication ID

22487971

1 reference